ホーム › 非小細胞肺癌 › ジョージア州 › Atlanta
Atlanta、GAにおける非小細胞肺癌の臨床試験
Atlantaとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する47件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Northside Hospital, Atlanta
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Winship Cancer Institute of Emory University, Atlanta
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- Emory University, Atlanta
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
- 他1件
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
被験者募集中第2相
- Emory Winship Cancer Institute, Atlanta
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
被験者募集中第3相
- Winship Cancer Institute of Emory University, Atlanta
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- Piedmont Healthcare, Inc, Atlanta
- Winship Cancer Institute, Atlanta
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
被験者募集中第3相
- Piedmont Atlanta Hospital ( Site 4000), Atlanta
- Emory University School of Medicine-Phase I ( Site 0056), Atlanta
- Northside Hospital ( Site 0055), Atlanta
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Emory University Winship Cancer Institute, Atlanta
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Grady Health System Correll Pavilion, Atlanta
- Piedmont Healthcare, Atlanta
- Piedmont Cancer Institute, Atlanta
- 他1件
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
被験者募集中第2相
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- Winship Cancer Institute, Atlanta
Pan-tumor MRD Study
被験者募集中観察研究
- Piedmont Cancer Institute, Atlanta
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Atlanta
- Research Site, Atlanta
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
被験者募集中第1相
- Emory Winship Cancer Institute, Atlanta
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
被験者募集中第2/3相
- Piedmont Healthcare, Atlanta
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
被験者募集中第1/2相
- Winship Cancer Institute at Emory University, Atlanta
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Atlanta
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
被験者募集中第3相
- Piedmont Cancer Institute, Atlanta
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
被験者募集中第3相
- Piedmont Cancer Institute OneOncology, Atlanta
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
被験者募集中第1/2相
- Emory University, Atlanta
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Piedmont Cancer Institute, PC, Atlanta
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Emory University School of Medicine- Grady Campus, Atlanta
- Winship Cancer Institute, Emory University, Atlanta
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- Piedmont Cancer Institute, PC, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
被験者募集中第1相
- Emory University, Atlanta
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
被験者募集中第1/2相
- Emory University, Atlanta
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
被験者募集中第2相
- Emory Winship Cancer Institute, Atlanta
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Emory University School of Medicine, Atlanta
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Emory University, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
被験者募集中第1/2相
- Winship Cancer Institute - Emory University, Atlanta
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
被験者募集中第3相
- Emory University - Winship Cancer Institute, Atlanta
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
被験者募集中第1/2相
- Winship Cancer Institute, Emory University, Atlanta
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Research Site, Atlanta
Study of XB010 in Subjects With Solid Tumors
被験者募集中第1相
- Winship Cancer Institute, Atlanta
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Northside Hospital, Atlanta
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
被験者募集中第2相
- USA10-0, Atlanta
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
被験者募集中第1相
- Winship Cancer Institute at Emory University, Atlanta
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Piedmont Healthcare, Atlanta
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- 他3件
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 111, Atlanta
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
被験者募集中第1相
- Emory University Hospital/Winship Cancer Institute, Atlanta
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Northside Hospital, Atlanta
Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
被験者募集中早期第1相
- Emory University/Winship Cancer Institute, Atlanta
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
被験者募集中第2相
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- Morehouse School of Medicine (MSM), Atlanta
- Piedmont Healthcare, Atlanta
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 114, Atlanta
- Research Site 139, Atlanta
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Atlanta
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Atlantaにおける他の研究
- がん（全種類）49件の研究
- 多発性骨髄腫42件の研究
- 乳がん41件の研究
- 前立腺がん33件の研究
- 急性骨髄性白血病31件の研究
- 卵巣がん29件の研究
- 大腸癌29件の研究
- 肺がん29件の研究
- 転移性癌28件の研究
- 大うつ病性障害25件の研究
- 心不全25件の研究
- 頭頸部扁平上皮癌24件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。